

AWARD NUMBER: W81XWH-21-1-0293

TITLE: Targeting NK Cells With Tofacitinib: A Novel Treatment for ALS

PRINCIPAL INVESTIGATOR: Benjamin J. Murdock

CONTRACTING ORGANIZATION: Regents of the University of Michigan, Ann Arbor, MI

REPORT DATE: May 2023

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE May 2023		2. REPORT TYPE Annual		3. DATES COVERED 15Apr2022-14Apr2023	
4. TITLE AND SUBTITLE Targeting NK Cells With Tofacitinib: A Novel Treatment for ALS				5a. CONTRACT NUMBER AL200064	
				5b. GRANT NUMBER W81XWH-21-1-0293	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Benjamin J. Murdock				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Regents of the University of Michigan 3003 S. State St Ann Arbor, MI 48109-1274				8. PERFORMING ORGANIZATION REPORT NUMBER AWD017710	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT <p>Though the cause or causes of amyotrophic lateral sclerosis (ALS) are currently unknown, an increasing body of work suggests that the immune system plays a key role in disease progression. Previous studies in mouse models of ALS, as well as our own preliminary data, demonstrate that altering levels of specific immune populations can affect the disease course. Thus, modulating specific immune cell populations may be a viable therapeutic strategy, but care must be taken to preserve the function of protective immune populations.</p> <p>NK cells are immune cells that play a key role in combating cancer and infection but are also responsible for eliminating damaged or dying cells. NK cells are more activated in the blood of ALS subjects, accumulate in the spinal cord of ALS mice, and ALS motor neurons are more vulnerable to NK cell-mediated damage. Our preliminary data suggest that depletion of NK cells from the periphery reduces neuroinflammation and extends survival in mouse models.</p> <p>Tofacitinib is an immune modulating drug that is commercially available for use in rheumatoid arthritis. Not only does it alter immune polarization towards a less destructive immune phenotype, it has been shown to reduce NK cell levels in human subjects in a dose-dependent manner. In addition, it preserves the levels of protective immune cells, such as CD4 T cells. Our preliminary data show that tofacitinib suppresses NK cell activity <i>in vitro</i> and reduces peripheral NK cell levels in mice. The objective of this proposal is therefore to use tofacitinib to delay disease progression in a pre-clinical mouse model of ALS using both prevention and intervention drug regimens. In parallel, we will determine if tofacitinib blocks activity in NK cells taken from the blood of ALS subjects, determine the mechanism by which NK cells damage neurons, and determine whether tofacitinib can block this pathway.</p> <p>Overall, successful completion of the proposed studies will offer incredible insight into the potential efficacy of tofacitinib for ALS, and at the same time provide important knowledge regarding the contribution and mechanisms of NK cell cytotoxicity in ALS that will facilitate therapeutic and biomarker discovery. These outcomes will thus have a highly significant impact on treatment options for subjects with ALS.</p>					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	28	USAMRDC

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	9
5. Changes/Problems	9
6. Products	10
7. Participants & Other Collaborating Organizations	11
8. Special Reporting Requirements	12
9. Appendices	12

1. INTRODUCTION

The current project examines the ability of an immunomodulatory drug, tofacitinib, to slow ALS progression via the suppression of natural killer (NK) cells. To do this, three main studies are being conducted: 1) treatment of SOD1^{G93A} male and female mice with either high or low doses of tofacitinib and assessing the impact on physical phenotype and immunophenotype, 2) treatment of primary NK cells isolated from control and ALS patient with tofacitinib to assess the impact on NK cell cytotoxicity; determine whether specific populations of ALS patients may benefit from tofacitinib treatment, and 3) explore the mechanisms by which NK cells induce neuronal cell death, including the secretion of extracellular vesicles and/or pro-apoptotic factors.

2. KEYWORDS

Amyotrophic lateral sclerosis, ALS, Natural killer cells, NK cells, immune system, tofacitinib, Xeljanz, exosomes, extracellular vesicles

3. ACCOMPLISHMENTS

Major goals:

1a. Treat ALS mice with tofacitinib both before and after disease onset with low or high doses of tofacitinib

1b. Immunophenotype ALS mice at end stage of disease


2a. Assess the cytotoxicity of ALS NK cells and the impact of tofacitinib

2b. Determine mechanisms of NK cell-mediated neuronal apoptosis and impact of tofacitinib

Milestone	Year 1	Year 2
1a. Treat ALS mice with tofacitinib prior to disease onset	Yellow	Yellow
1a. Treat ALS mice with tofacitinib after to disease onset	White	Yellow
1b. Immunophenotype mice at end stage of disease	White	Green
2a. Assess cytotoxicity of ALS NK cells and impact of tofacitinib	Blue	Blue
2b. Determine mechanism of contact-free apoptosis and impact of tofacitinib	Blue	White
Manuscript and grant preparation	White	Brown

Accomplishments of these goals

Goal 1a (95% complete). We examined the impact of tofacitinib on ALS in the SOD1^{G93A} mouse model. Male and female mice were treated with high or low doses of tofacitinib pressed into chow. Mice were then assessed for changes in weight, grip strength, agility (using a rotarod), and survival time. In addition, we have sectioning and staining spinal cord cross sections of the spinal cord of euthanized mice to assess changes in motor neuron counts.




We have completed the treatment of all cohorts of ALS mice ($n = 120$) and found that low doses of drug significantly increases the survival of ALS mice at lower doses (5 mg/kg) (Fig 1.); we also found that intermittent

treatment (weekly drug cycles) enhanced drug response at both low and high doses. The preventative and intervention high-dose studies were discontinued after the initial cohort showed a clear lack of efficacy. The drug did not alter loss of agility on the rotarod or loss of grip strength (data not shown). Tofacitinib also accelerated weight loss, despite the benefits to survival (data not shown). Mouse spinal cords and neuromuscular junctions (NMJs) have been sectioned and stained from the first two mouse cohorts, and staining is being completed on the last cohort. Data analysis will be completed within the next two months.

Goal 1b (85% complete): We examined whether tofacitinib alters the immune response in ALS. Control and ALS mice were immunophenotyped at the time of sacrifice at the terminal end stage of disease. Peripheral blood and spinal cord tissue was collected to examine the immune composition using flow cytometry or to examine gene expression using RNA-Seq.

Half of the mice from the initial cohort of mice were immunophenotyped at the time of death using flow cytometry. Full flow analysis has been performed on half of the initial cohort; data has been collected from the remaining mice and data is being analyzed. We have developed an automated pipeline which collates the raw data to generate final cells counts and cellular MFI. This system will also allow us to easily match these data with other metrics in individual mice such as survival, motor neuron counts, etc. In the blood, tofacitinib suppressed NK cell levels, and intermittent treatment appears to increase the levels of protective CD4 T cells (**Fig. 2A**). These data are based on the first mouse cohort and do not yet contain the full data set. Similarly, in the spinal cord, there is a trend toward reduced microglial levels following tofacitinib treatment (**Fig. 2B**). With regards to microglia surface marker expression, there is a trend towards reduced microglial activation (data was not divided by sex in the interest of space), and there is a trend towards increased F4/80 expression. Similar trends were seen in low dose mice (data not shown). As with the initial cohort of mice, we will be immunophenotyping all mice in the upcoming cohorts to increase our n-value.



For RNA-Seq all tissue (blood and spinal cord) has been collected. RNA is being isolated from all tissue and will be completed within the next month; initial testing shows that RNA levels are of sufficient quality to use RNA-Seq. All samples will be submitted to the University of Michigan Advanced Genomics Core. Following generation of the data, our bioinformatics team will identify dysregulated genes in ALS mice versus control mice and also determine whether tofacitinib reverses this dysregulation and whether genes that are dysregulated in the blood are also dysregulated in the spinal cord.

Finally, when all data have been collected, our biostatistical team will correlate different metrics with one another. For instance, we will examine whether specific gene dysregulation predicts survival or immune infiltration into the spinal cord.


Goal 2a (95% complete): We examined whether tofacitinib can suppress activity in NK cells isolated from control and ALS subjects, and whether specific groups of patients might benefit from treatment. NK cells were isolated from the peripheral blood of control and ALS study subjects and co-cultured with target cancer cells in the presence or absence of tofacitinib. Target cell death was used to quantify NK cell cytotoxicity. In a subset of patient samples cytokine gene expression levels were also analyzed using qRT-PCR.

We examined the impact of tofacitinib on primary NK cell cytotoxicity isolated from control and ALS patients. Of the projected patient samples taken from the ALS Biorepository (20 control and 50 ALS) we have analyzed samples from 196 control and ALS patients meaning we easily passed our target goal for sample number. We have shown that tofacitinib consistently suppresses cytotoxicity in NK cells derived from ALS patients and suppresses NK cell cytokine production (published in *Frontiers in Immunology* last year, see **Appendix for Figueroa-Romero et al. Figure 3**). This data set has been finalized and we are currently waiting for the biostatistical analysis of the mouse study to conclude before moving on to this analysis. When the analysis begins, we will determine whether specific groups or demographics of ALS patients respond best to the treatment. In addition, we will use peripheral immunophenotyping from our ongoing R01 study to identify blood-based immune markers that can predict the NK cell response to tofacitinib treatment.

Goal 2b (60% complete): We examined the underlying mechanisms by which NK cells induce neuronal death and whether this process can be suppressed by tofacitinib. We co-cultured NK cells with inducible neurons (iNeurons) derived from ALS patients with and without tofacitinib. In addition, we have been examining the mechanisms by which

NK cells induce death through a contact-independent pathway (and whether tofacitinib blocks this pathway).

We have shown that tofacitinib reduces NK cell toxicity to iNeurons (published in *Frontiers in*



Immunology, see Appendix for Figueroa-Romero et al. Figure 2). We were able to isolate extracellular vesicles (EVs) from NK cells (Fig. 3A), and we found that tofacitinib alters the kinetics of EV release from NK cells (Fig. 3B). iNeurons co-cultured with EVs take up the EVs and their cargo (Fig. 3C). However, while co-culturing iNeurons with NK cell-derived EVs accelerates cell death, treating NK cells with tofacitinib does not alter the cytotoxicity of the EVs following short (Fig. 3D) or overnight culture (Fig. 3E). Studies still need to be conducted to determine if tofacitinib alters the cargo of the NK cell EVs, and what cargo within the EVs is increasing the death in iNeurons. Note that little progress has been made on this goal in the last year. The primary researcher associated with this project, Dr. Claudia Figueroa-Romero, left our research group in July of 2022, and we spent 9 months attempting to hire a replacement. As we were unable to find a suitable candidate, one of the members of our research team, Dr. Bhumsoo Kim, has taken over the project and is in the process of repeating the experiments initially started by Dr. Figueroa-Romero. We have filed for – and received – a no-cost extension for the project to allow us to complete this goal of the study.

Stated goals not met:

With the exception of Goal 2b (see above), all samples have been collected and processed (or are nearing completion in the case of the RNA-Seq samples). Currently the primary obstacle is the rate at which the biostatistical team can process and analyze the final data. We anticipate that the mouse data will be completed in the next two months, the RNA-Seq data in the next three months, and the analysis of NK cell cytotoxicity in the next four months.

Training

Nothing to report.

Professional development

Though training and professional development was not a part of the proposed research, Dr. Murdock has attended the Target ALS annual conference and the CREATe Consortium annual conference to disseminate his research. We have begun meeting with venture capital firms to secure funding for future clinical trials. To this end, we have also been working with Dr. Max Shtein and the University of Michigan to create a formulation of the drug that we can propose to venture capital firms.

Next reporting period goals

During the first year of the study we conclusively showed that tofacitinib suppresses NK cell-mediated cytotoxicity and cytokine release. Treatment of NK cells with tofacitinib protects iNeurons from NK cell-mediated cytotoxicity. In the last year we finished collecting human samples for cytotoxicity analysis and completed collecting all samples and data from the mouse study (though it is still being analyzed). The primary goals of the next year will therefore to a) collate and analyze the mouse data for publication, b) analyze and publish the cytotoxicity data, and c) finish the NK cell/exosome aspect of the study now that Dr. Bhumsoo Kim has taken over for Dr. Figueroa-Romero.

All human samples are taken from the ALS Biorepository, therefore patient enrollment and accrual is not applicable.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

The data suggest that tofacitinib can be used to treat ALS; however, dosing may be important for successful use. Moreover, the data suggest that previous clinical trials using immunomodulatory drugs may have failed due to poor dosing regimens. We showed conclusively that tofacitinib can suppress NK cell function, including cytotoxicity to iNeurons. Moreover, we demonstrated that EVs isolated from NK cells induce neuronal death, suggesting a new mechanism by which neurons die in ALS. So far, tofacitinib does not appear to affect EV-mediated cell death, but further assays are needed.

What was the impact on other disciplines?

While the project is geared primarily towards ALS, we have discovered a potential new mechanism by which neurons die (NK cell-derived EVs). In addition, we show that tofacitinib suppresses NK cell numbers and activity, meaning the drug may have clinical utility in other, NK cell-driven diseases. Finally, our finding that lower doses of immunomodulatory drugs may be more beneficial than higher doses suggest that precise dosing may be necessary when using similar drugs in ALS or in other diseases.

What was the impact on technology transfer?

Nothing to report, though we will begin looking for partnership with venture capital to fund clinical trials.

What was the impact on society beyond science and technology?

Nothing to report.

5. CHANGES/PROBLEMS

Changes in approach

The only minor change in our approach has been the use of alternate methods of characterizing neuronal cell death in vitro assays; these changes were first outlined in our proposal under Potential Obstacles and Alternative Strategies. In brief, two factors have pushed us away from our initial, proposed imaging assay for assessing neuronal survival. The first is technical: unlike primary neurons, iNeurons have proven to be incredibly difficult to work with as they tend to clump

together over time and also move around the plate. This makes it difficult for the automated software to track. The second problem involves personnel: our consultant Dr. Sami Barmada – who specializes in the neuronal imaging system – has experienced significant personnel turnover making it difficult to render us assistance on a consistent basis. As such, we begun using alternate methods to assess iNeuron survival.

Actual or anticipated problems or delays and actions or plans to resolve them

Aside from neuronal assays, the primary problems have been associated with personnel and supply chain issues. In our own research group Dr. Lisa McGinley, who was originally responsible for the in vitro iNeuron assays, accepted a new job in September of 2021. Dr. Murdock first took up some of her responsibilities, followed by Dr. Claudia Figueroa-Romero. However, Dr. Figueroa-Romero left the project in July of 2022; as we were unable to find a long-term replacement for Dr. Figueroa-Romero Dr. Bhumsoo Kim has taken over the work examining NK cell and extracellular vesicles.

In terms of supply chain issues, there were significant delays in ordering tofacitinib from the supplier, which pushed back the timing of the mouse study somewhat. For instance, one shipment of the drug chow had been opened prior to arriving. It is uncertain whether this was a result of a drug inspection or attempted theft; in either case, breaking the seal on the bags of chow resulted in bacterial contamination, and the chow was not allowed into the vivarium. All of these issues have now been resolved, however.

Changes that had a significant impact on expenditures

Most of the aforementioned changes have had some impact on expenditures. In particular, changing personnel altered the money being spent on salary support, and the use of alternative iNeuron assays has resulted in a small price increase. And obviously the loss of the chow due to contamination has resulted in additional costs. The delays to the mouse study also meant that the subsequent cohorts of mice were not ordered during the first year of the study as anticipated. We filed for – and received – a no-cost extension that allow us to spend the remaining funds on the RNA-Seq analysis as well as fund the remaining work on the extracellular vesicle aspect of the study.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to report

6. PRODUCTS

Publications, conference papers, and presentations

Journal publications

We published the first manuscript associated with the project in *Frontiers in Immunology*:

Authors: Claudia Figueroa-Romero, Alina Monteagudo, Benjamin J. Murdock (co-first authors), Joshua P. Famie, Ian F. Webber-Davis, Caroline E. Piecuch, Samuel J. Teener, Crystal Pacut, Stephen A. Goutman and Eva L. Feldman.

Title: Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis

Journal: *Frontiers in Immunology*. 2022 Feb 7;13:773288.

PMID: 35197969

Status: Published

Acknowledged federal support: YES

Books or other non-periodical, one-time publications

Nothing to report

Other publications, conference papers and presentations

Dr. Murdock recently presented the current data at the annual Target ALS conference in Cambridge, MA. This international conference hosts ALS researchers from across the world.

Abstract for the conference presentation is in the appendix.

Website(s) or other Internet site(s)

Nothing to report

Technologies or techniques

Nothing to report

Inventions, patent applications, and/or licenses

Dr. Murdock is listed as inventor on patent issue number US10660895, held by University of Michigan titled "Methods for Treating Amyotrophic Lateral Sclerosis" that targets immune pathways for use in ALS therapeutics. More specifically, the patent covers the use of ALL JAK/STAT inhibitors for the treatment of ALS including tofacitinib.

Other products

Nothing to report

7. PARTICIPANTS AND OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: Benjamin Murdock

Project Role: Principal Investigator

Nearest person month worked: 3 (each year)

Contribution to Project: Dr. Murdock oversaw the project and was involved in most aspects of the bench work. He was also responsible for writing the 2022 Figueroa-Romero et al. manuscript which contained data from this study.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Lisa McGinley

Project Role: Collaborator, senior personnel

Nearest person month worked: 2 (Year 1)

Contribution to Project: Dr. McGinley oversaw early in vitro work using iNeuron culture assays, particularly assays using EVs. Her overall % of salary is low because she left the project last year.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Claudia Figueroa-Romero

Project Role: Collaborator, senior personnel

Nearest person month worked: 2 (Year 2)

Contribution to Project: Dr. Figueroa-Romero replaced Dr. McGinley on the in vitro work using iNeuron culture assays and EVs. Her overall % of salary is low because she left the project last year.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Bhumsoo Kim

Project Role: Collaborator, senior personnel

Nearest person month worked: 1.8 (Year 3 from no-cost extension)

Contribution to Project: Dr. Kim replaced Dr. Figueroa-Romero and is currently completing the assays using EVs. His effort has been set to 1.8 months for the next year.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Faye Mendelson

Project Role: Technician

Nearest person month worked: 9 (Year 1)

Contribution to Project: Ms. Mendelson runs the mouse studies for the research group for the first year before her departure. She was responsible for drug administration and physical phenotyping. She also assisted with mouse harvest, collection of tissue for immune analysis, and some of the in vitro study work.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Andrew Carter

Project Role: Technician (Year 2)

Nearest person month worked: 12

Contribution to Project: Mr. Carter replaced Ms. Mendelson on the mouse studies for Year 2 of the study. He was responsible for drug administration and physical phenotyping. He also assisted with mouse harvest, collection of tissue for immune analysis, and some of the in vitro study work.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: John Hayes

Project Role: Technician

Nearest person month worked: 5 (each year)

Contribution to Project: Mr. Hayes worked primarily on the in vitro studies, both with primary cells taken from the ALS Biorepository as well with the in vitro culture models examining iNeurons and EVs. He also assisted Ms. Mendelson with mouse phenotyping as well as harvests.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Ian Webber-Davis

Project Role: Technician

Nearest person month worked: 12 (Year 2)

Contribution to Project: Mr. Webber-Davis has worked on all aspects of the study including mouse studies, *in vitro* studies, and *ex vivo* studies. He has also been assisting Bhumsu Kim with the in vitro culture models examining iNeurons and EVs.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Name: Kai Guo

Project Role: Statistician/informatician

Nearest person month worked: 2 (Year 2)

Contribution to Project: Dr. Guo has worked with us on the quality control and analysis the RNA-Seq data in Aim 1b.

Funding Support: All funding for this study was provided by the DoD award W81XWH-21-1-0293.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Dr. Lisa McGinley left the research group for a position at the California Institute of Regenerative Medicine; Dr. Murdock has taken on some of her work duties. Dr. Claudia Figueroa-Romero has also helped worked with Dr. Murdock on the project, though her salary has been covered by other sources of funding.

What other organizations were involved as partners?

Financial: The ALS Association funds part of Dr. Murdock's salary for several parallel tofacitinib studies; however, they are not directly involved in the project currently under review.

8. SPECIAL REPORTING REQUIREMENTS

Collaborative Awards

Not applicable.

Quad charts

Not applicable.

9. APPENDICES

Target ALS presentation abstract

Determining the impact of tofacitinib treatment on ALS mice

Previous studies have demonstrated that the immune system plays a role in ALS pathology. However, previous clinical trials using immunosuppressive drugs have failed, likely because these drugs suppress protective immune mechanisms in addition to suppressing destructive mechanisms. Targeted therapeutics which suppress specific immune populations and mechanisms may therefore be more effective in treating ALS than global immunosuppressive drugs. We have shown that natural killer (NK) cells likely play a role in accelerating ALS progression, making these cells attractive targets for therapeutic intervention. Tofacitinib, a JAK/STAT inhibitor used to treat rheumatoid arthritis, may block the cell signaling pathway needed for NK cell survival and function; tofacitinib may therefore be a viable treatment for use in ALS. We show that tofacitinib suppresses NK cell cytotoxicity and cytokine production in both an NK cell line as well as primary NK cells isolated from ALS subjects. In addition, treatment of ALS mice with tofacitinib reduces peripheral NK levels, suppresses neuroinflammation, and can extend survival following some treatment regimens. These data suggest that tofacitinib may be a viable drug for future ALS clinical trials.



Tofacitinib Suppresses Natural Killer Cells *In Vitro* and *In Vivo*: Implications for Amyotrophic Lateral Sclerosis

OPEN ACCESS

Edited by:

Lutz Walter,
Leibniz Institute for Primate Research,
Germany

Reviewed by:

Gaetane Nocturne,
U1184 Centre de recherche en
Immunologie des Infections virales et
des maladies auto-immunes
(INSERM), France
Adelheid Cerwenka,
Heidelberg University, Germany

*Correspondence:

Eva L. Feldman
efeldman@umich.edu

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology

Received: 09 September 2021

Accepted: 18 January 2022

Published: 07 February 2022

Citation:

Figuroa-Romero C,
Monteagudo A, Murdock BJ,
Famie JP, Webber-Davis IF,
Piecuch CE, Teener SJ, Pacut C,
Goutman SA and Feldman EL (2022)
Tofacitinib Suppresses Natural Killer
Cells *In Vitro* and *In Vivo*: Implications
for Amyotrophic Lateral Sclerosis.
Front. Immunol. 13:773288.
doi: 10.3389/fimmu.2022.773288

**Claudia Figuroa-Romero[†], Alina Monteagudo[†], Benjamin J. Murdock[†], Joshua P. Famie,
Ian F. Webber-Davis, Caroline E. Piecuch, Samuel J. Teener, Crystal Pacut,
Stephen A. Goutman and Eva L. Feldman^{*}**

Department of Neurology, University of Michigan, Ann Arbor, MI, United States

Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS target. Tofacitinib is an FDA-approved immunomodulating small molecule which suppresses immune cell function by blocking proinflammatory cytokine signaling. This includes the cytokine IL-15 which is the primary cytokine associated with NK cell function and proliferation. However, the impact of tofacitinib on NK activation and cytotoxicity has not been thoroughly investigated, particularly in ALS. We therefore tested the ability of tofacitinib to suppress cytotoxicity and cytokine production in an NK cell line and in primary NK cells derived from control and ALS participants. We also investigated whether tofacitinib protected ALS neurons from NK cell cytotoxicity. Finally, we conducted a comprehensive pharmacokinetic study of tofacitinib in mice and tested the feasibility of administration formulated in chow. Success was assessed through the impact of tofacitinib on peripheral NK cell levels in mice. We found tofacitinib suppressed IL-15-induced activation as measured by STAT1 phosphorylation, cytotoxicity, pro-inflammatory gene expression, and pro-inflammatory cytokine secretion in both an NK cell line and primary NK cells. Furthermore, tofacitinib protected ALS neurons from NK cell-mediated cytotoxicity. In mice, we found tofacitinib bioavailability was 37% in both male and female mice; using these data we formulated mouse containing low and high doses of tofacitinib and found that the drug suppressed peripheral NK cell levels in a dose-dependent manner. These results demonstrate that tofacitinib can suppress NK cell function and may be a viable therapeutic strategy for ALS.

Keywords: ALS, NK cells, immune system, tofacitinib, JAK/STAT

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease resulting in death of the motor neurons (1). The average patient lifespan is 2 to 4 years from disease diagnosis, and few therapeutic options exist. However, an increasing body of literature suggests that the immune system is involved in the pathogenesis of ALS (2, 3), with specific immune cell populations likely contributing to disease progression in ALS mouse models (4–9). Similarly, in human ALS patients, changes in peripheral immune cell numbers and activation state correlate with disease progression (10–13). Unfortunately, suppressing the immune system can have unintended and sometimes fatal consequences. General immune suppression increases susceptibility to pathogens and cancer (14); it may also accelerate ALS progression (15, 16) since several immune populations perform protective functions, which slow disease progression (10, 11). The loss of protective immune cell populations likely explains previous failures of immunosuppressive drugs for ALS. Conversely, certain immune cell populations accelerate ALS (6–10, 12, 13); thus, targeting these specific immune populations may be a more nuanced and potentially effective approach for slowing disease progression than global immune suppression.

Generally, immune cells do not attack the body's own cells under homeostatic conditions. However, natural killer (NK) cells destroy the body's own cells when they become cancerous, infected, or damaged (17, 18). NK cells may also contribute to ALS progression (7, 8, 10, 13); we and others have found elevated NK cell levels in the peripheral blood of ALS patients (10, 11) and NK cells accumulate in the spinal cord of ALS mice (7, 8, 19). Moreover, during ALS, motor neurons stop expressing major histocompatibility complex proteins, which mark them as self, protecting them from NK cell-mediated cytotoxicity (20, 21). This suggests a particular vulnerability of motor neurons to NK cells in ALS. Finally, NK cells drive a pro-inflammatory microglia phenotype and simultaneously suppress protective regulatory T cells during ALS (7). Thus, drugs targeting NK cells may prove a viable therapeutic option for ALS, both by blocking NK cell cytotoxicity as well as preventing a pro-inflammatory cascade in the central nervous system.

Tofacitinib is a small molecule pharmaceutical approved for treating multiple immune disorders, including rheumatoid arthritis (22), ulcerative colitis (23), and psoriasis (24). The drug suppresses pro-inflammatory immune activation by blocking the JAK/STAT pathway of the adaptive immune system (25, 26) while preserving innate immune activity and regulatory function (27, 28). However, cytokines associated with NK cell survival and function, including IL-15, signal through the JAK/STAT pathway as well (29–32) and would also be blocked by tofacitinib (33). Indeed, several studies suggest tofacitinib suppresses NK cell numbers in the peripheral blood of mice (34, 35) and humans (36). However, little research has been performed to examine the impact of tofacitinib on NK cell activation. Thus, tofacitinib could potentially block NK cell cytokine production and cytotoxicity in addition to lowering overall levels, providing added benefits as an ALS treatment.

In addition, tofacitinib would target NK cells and pro-inflammatory pathways while preserving protective immune function (28) thus overcoming previous failures of previous immune-based therapies for ALS (37).

The present study therefore evaluated the ability of tofacitinib to suppress NK cell cytokine expression and cytotoxicity *in vitro*, both in an NK cell line and in primary NK cells derived from ALS participants. We also investigated whether tofacitinib suppressed NK cell cytotoxicity to inducible neurons (iNeurons) differentiated from ALS patient-derived inducible pluripotent stem cells (iPSCs). Finally, we examined tofacitinib pharmacokinetics in mice as well as the impact *in vivo* on the immune system, since these data have not been previously established and are crucial to future preclinical studies of ALS. Our study found that tofacitinib suppresses NK cell cytotoxicity and cytokine production *in vitro* and suppresses NK cell levels *in vivo* in mice after oral administration in food. These data demonstrate that tofacitinib may be a viable ALS treatment and establish a foundation for future preclinical studies.

METHODS

Study Participants

Healthy control participants without a history of neurodegenerative disease, chronic inflammatory disease, collagen vascular disease, or immunomodulatory medication use were recruited through the University of Michigan Institute for Clinical & Health Research. In parallel, ALS participants meeting a diagnosis of ALS by El Escorial Criteria were recruited during clinical visits at the University of Michigan Pranger ALS Clinic as previously described (13). All study participants provided oral and written informed consent and the study received ethics board approval by the University of Michigan Medical School Institutional Review Board (HUM00028826).

Cell Lines and Primary Human NK Cells

Cell Lines

The NK-92 NK cell line (ATCC Cat# CRL-2408, RRID : CVCL_3755) and K-562 leukemia cell line (ATCC Cat# CCL-243, RRID : CVCL_0004) were acquired from ATCC (Manassas, VA). NK-92 cells were grown in NK media [Alpha's Modification of Medium Essential Eagle media (STEMCELL Technologies cat #36453) supplemented with 12.5% horse serum (Gibco cat #16050122), 12.50% fetal bovine serum (FBS, Sigma Aldrich cat #F4135), 1% penicillin/streptomycin (Gibco cat #15140122), 0.2 mM myo-inositol (Sigma-Aldrich cat #17508), 0.02 mM folic acid (Sigma-Aldrich cat #F8758), and 0.1 mM β -mercaptoethanol (Sigma cat #M7522) and 645.2 nM IL-2 (PeproTech cat #200-02)]. K-562 cancer cells were grown in K-562 media [Iscove's Modified Dulbecco's Medium (STEMCELL Technologies cat #36150) with 10% FBS and 1% penicillin/streptomycin (Gibco cat #15140122)]. Human-derived iPSC lines #1021 (control) and #265 (sporadic ALS, sALS) were obtained from the University of Michigan ALS Biorepository (38). Control and ALS iPSCs were used to generate iNeurons by suppressing the polypyrimidine-tract-binding (PTB) protein, as previously described (39). Briefly, iPSCs

were cultured on poly-D-lysine (50 µg/L, Sigma cat #p1149)/ laminin (1:100, Sigma cat #L2020) coated plates in iPSC media [E8 media (Gibco cat #A1517001) supplemented with iROCK Y27632 (Fisher cat #BDB562822)] in 6-well plates at a density of 1×10^5 cells/well. The following day (Day 1), the media was changed to iNeuron media #1 [E8 media supplemented with 1X N2 supplement (Gibco, cat #17502-048), 1X NEAA supplement (Gibco cat #11140-050), 10 ng/mL BDNF (Peprotech cat #450-02), 10 ng/mL NT3 (Peprotech cat #450-03), 0.2 µg/mL mouse laminin (Sigma cat #L2020), 2 mg/mL doxycycline (Sigma cat #D3447)]. On Day 2, the cells were changed to iNeuron media #2 [$\frac{1}{2}$ E8, $\frac{1}{2}$ DMEM/F12 (Gibco cat #11320-033), 1X N2 Supplement, 1X NEAA supplement, 10 ng/mL BDNF, 10 ng/mL NT3, 0.2 µg/mL laminin, 2 mg/mL doxycycline]. On Day 3, cells were changed to iNeuron media #3 [Neurobasal-A (Gibco cat #12349-015), 1X B27 supplement (Gibco cat #17504-044), 1X Glutamax supplement (Gibco cat #35050-061), 10 ng/mL BDNF, 10 ng/mL NT3, 0.2 µg/mL mouse laminin, 2 mg/mL doxycycline]. Additional media #3 was added on Day 6 and Day 8. iNeurons were differentiated for 10 days prior to treatment.

Primary NK Cells

10 mL of whole blood was collected from control and ALS participants, as previously described (10, 12, 13). NK cells were enriched using RosetteSep Human NK isolation cocktail (STEMCELL Technologies cat #15025) and cultured in NK media supplemented with 645.2 nM IL-2 or IL-2 + 2.33 nM IL-15 (PeproTech cat #200-15) for co-culture assays. All cells were grown at 37°C in 5% CO₂.

NK-92 IL-15 Stimulation and Tofacitinib Treatment Paradigms

NK-92 cells were cultured using two IL-15/tofacitinib paradigms (Figure 1A). In the first paradigm (P1), NK-92 cells were cultured for two hours with 2.33 nM IL-15 in serum-free NK media prior to overnight treatment with 50 nM tofacitinib (Selleckchem cat #CP-690550). In the second treatment paradigm (P2), NK-92 cells were cultured overnight with 50 nM tofacitinib in serum-free NK media prior to two-hour culture with 2.33 nM IL-15. 50 nM concentration of tofacitinib was used based on previous *in vitro* immune studies (40, 41). For each treatment paradigm, three groups of NK-92 cells were generated: cells receiving no IL-15 and no tofacitinib (Unstimulated), cells receiving only IL-15 (Stimulated) or cells receiving IL-15 stimulation and tofacitinib treatment (Treated). NK-92 cells were then collected, washed, and analyzed for STAT1 phosphorylation (P-STAT), cytotoxicity towards K-562 cells, granzyme B and perforin expression, or cytokine gene expression (see below).

Primary NK Cell Stimulation and Tofacitinib Treatment

1×10^5 human primary NK cells were cultured in a 48-well plate (Corning cat #3524) in NK media supplemented with 645.2 nM IL-2 + 2.33 nM IL-15 ± 50 nM tofacitinib for two hours at 37°C in 10% CO₂. Unlike NK-92 cells, primary NK cells were provided

additional IL-2 cytokine stimulation to enhance survival in culture (data not shown) (42). The cells were washed and pelleted for subsequent western blot, quantitative real-time PCR (qRT-PCR), and cytotoxicity analysis.

Western Blot Analysis

NK-92 or primary NK cells were lysed in RIPA buffer (Pierce/Thermo Fisher Scientific cat #89901) supplemented with cOmplete mini, EDTA-free protease inhibitors (Roche cat #11836170001), sonicated, and centrifuged. Protein samples were resolved by SDS-PAGE in 10% acrylamide gels, transferred to Immobilon-FL PDVF membranes (Millipore cat #IPFL00010), and immunoblotted with the indicated primary antibodies: rabbit anti-STAT1 (D1K94) (Cell Signaling Technologies, CST, cat #14994S), rabbit anti-P-STAT1 (Y701) (CST cat #9167S), and rat anti- α -tubulin (Abcam cat #ab6160; RRID : AB_305328). Goat anti-rabbit (cat #7074S; RRID : AB_2099233) and anti-biotin horseradish peroxidase (HRP)-linked (cat #7075P5) secondary antibodies were used at 1:2000 (CST) and anti-rat IgG HRP-conjugated secondary antibody was used at 1:5000 (R&D cat #HAF005; RRID : AB_1512258). Densitometric analysis was performed Quantity One v.4.6.5 (Bio-Rad).

Cytotoxicity Assays

NK-92 Cells and K-562 Cells

Pre-treated NK-92 cells (Paradigm 1 or 2) were plated at a density of 1×10^6 NK-92 cells and co-cultured with 1×10^5 K-562 cells for two hours at a 10:1 ratio in a final volume of 500 µL followed by flow cytometric analysis of K-562 and NK-92 cell viability dye levels (positive levels indicating cell death, see below).

NK-92 Cells and iNeurons

1×10^6 NK-92 cells were starved for 2 hours in serum-free NK media, then treated with 50 nM tofacitinib or vehicle (dimethyl sulfoxide, DMSO) for 30 minutes prior to stimulation with 2.33 nM IL-15 for 4 hours (similar to the intervention treatment paradigm, P2). Treated NK-92 cells were re-suspended in 0.5 mL iNeuron media #3 and co-cultured for 2 hours with 10-day old iNeurons plated at 2×10^5 cells/well (NK-92:iNeuron = 5:1). At the end of the incubation, the media containing the NK-92 was removed and the iNeurons were washed with 1X PBS and released from the plates with Accutase (Innovative Cell Technologies cat #AT-104) for viability analysis *via* flow cytometry (see below).

Primary NK Cells and K-562 Cells

1×10^5 human primary NK cells were co-cultured with 1×10^5 K-562 cells at a 1:1 ratio were seeded to a 48-well plate (Corning) with NK media for 2 hours at 37°C in 5% CO₂ under one of three conditions: with 645.2 nM IL-2, with IL-2 + 2.33 nM IL-15, or with IL2 + IL-15 + 50 nM tofacitinib. Following co-culture, conditioned media was then collected and stored for subsequent analysis (see below). K-562 and primary NK cells were then washed with flow buffer [1000 mL 1X PBS + 20 mL FBS + 0.01 g




FIGURE 1 | Tofacitinib inhibits NK-92 cells function *in vitro*. **(A)** NK-92 cells were cultured with serum-free media under two culture paradigms: Paradigm 1 (P1) intervention treatment, whereby NK-92 cells were treated with IL-15 for two hours and then cultured overnight in the presence of tofacitinib (Treated), and Paradigm 2 (P2) prevention treatment where NK-92 cells were treated overnight with tofacitinib prior to two-hour IL-15 stimulation. **(B)** Stimulated and Treated NK-92 cells were assessed for STAT1 phosphorylation (P-STAT) following both culture paradigms. Representative immunoblots for Stimulated and Treated P-STAT1 and α -tubulin (internal reference) are shown. Quantitative data represent densitometric analysis, where total STAT1 and P-STAT1 signals were first normalized to α -tubulin then to P-STAT1 levels in Unstimulated cells; $n = 5$ independent experiments. **(C)** Unstimulated, Stimulated, and Treated NK-92 cells were co-cultured with K-562 cancer cells (10:1 ratio) following initial P1 or P2 culture paradigms. Flow cytometry was used to identify K-562 cells in the co-culture, and cell death was assessed by viability dye staining. K-562 cell death was quantitated for Stimulated and Treated NK-92 cells and normalized to Unstimulated NK-92 cells; $n = 10$ independent experiments. **(D)** Expression of the intracellular NK cell proteins perforin and granzyme B was determined by flow cytometry on Unstimulated, Stimulated, and Treated NK-92 cells using intracellular flow cytometry following P1 and P2 culture paradigms. Representative histograms are shown; gray peaks = Unstimulated NK-92 cells, red peaks = Stimulated NK-92 cells, blue peaks = Treated NK-92 cells show MFI. MFI from Stimulated and Treated cells were normalized to protein levels in Unstimulated NK-92 cells for quantitation; $n = 6$ independent experiments. **(E)** Gene expression of IL-10, TNF- α , and IFN γ cytokines was assessed in Unstimulated, Stimulated, and Treated NK-92 cells following P1 and P2 paradigms using qRT-PCR. Data for Stimulated and Treated cells were normalized to GAPDH expression then to the Unstimulated cells; $n = 3-4$ independent experiments. **(F)** Extracellular expression of IL-10, TNF- α , IFN- γ , granzyme B, and perforin was assessed for Stimulated and Treated NK-92 cells using a CD8/NK cell multiplex analysis following P1 and P2 treatment paradigms ($n = 8-13$ independent experiments). For all experiments, quantitative data is shown as the mean \pm SEM; **(A-E)** comparisons were made by Student's t-test; **(F)** comparisons were made using a paired t-test or a Wilcoxon test based on normality of the data. Horizontal dashed lines represent normalized Unstimulated NK-92 cell levels. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

NaN₃] and plated for analysis of both cell types using flow cytometry and viability dye (see below).

Quantitative Real-Time PCR (qRT-PCR)

RNA was isolated from NK-92 or primary NK cells using the RNeasy isolation kit (Qiagen cat #74104) and with RNA/DNA/RNase-free DNase treatment (Qiagen cat#79254). cDNA was generated using 0.5 µg of NK-92 RNA or 40 ng primary NK cell RNA and 5X iScript RT (Bio-Rad cat#1708840) in a 20 µL reaction following the manufacturer's protocol. The reactions were run in a PTC-200 Peltier Thermal Cycler (MJ Research). qRT-PCR was performed in triplicate using 10-µL reactions consisting of sequence specific TaqMan™ primers for human IL-10 (Hs00961622_m1), TNF-α (Hs00174128), IFN-γ (Hs00989291_m1), GAPDH (Hs02758991_g1), and γWHAZ (Hs03044281_g1); 2X gene expression Master Mix (Applied Biosystems/Thermo Fisher Scientific, cat #4369016) and 2 µL cDNA. C_T values were used to calculate ΔC_T and ΔΔC_T using GAPDH or γWHAZ as the internal references. Data were expressed as the mean of the relative quantity of gene expression ($2^{-\Delta\Delta C_T}$).

Multiplex Analysis of Cytokines and Secreted Proteins

The release of cytokines and pro-apoptotic factors by NK-92 and primary NK cells was assessed using the LEGENDplex Human CD8/NK Cell Panel (Biolegend, cat# 740267) according to the manufacturer's instructions. In brief, fluorescent beads were incubated with conditioned media from NK-92 or primary NK cells co-cultured with K-562 cancer cells, and flow cytometry (see below) was used to quantify IL-10, TNF-α, IFN-γ, granzyme B, and perforin in the conditioned media.

Mice

Mice were purchased from Jackson Laboratory (Bar Harbor, ME). Male and female C57BL/6 mice (Stock #000664; RRID : IMSR_JAX:000664) were used for initial tofacitinib pharmacokinetic assays. For tofacitinib efficacy studies, male and female non-carrier, wild-type (WT) control littermates of SOD1^{G93A} ALS mice were used (B6.Cg-Tg(SOD1*G93A)1Gur/J; Jackson Stock #004435). All mice were housed under specific pathogen-free conditions. Animals were fed 5L0D chow *ad libitum* when not treated. All mouse studies were performed in accordance with University of Michigan Institutional Animal Care & Use Committee approved protocols (approval #PRO00010247). Mouse studies were conducted in accordance with the United States Public Health Service's policy on Humane Care and Use of Laboratory Animals.

Tofacitinib Administration to Mice and Plasma Collection for Pharmacokinetic Assays

Tofacitinib was suspended at 2 mg/mL in PBS containing 5% DMSO and 10% PEG-400, which was administered by intravenous (IV) injection (10 mg/kg, 10 mice) or *per os* (PO) *via* gavage (20 mg/kg, 10 mice). At the given time points (0.083,

0.167, 0.25, 0.5, 1, 2, 4, 7, 16, and 24 hours), blood samples were collected using heparinized calibrated pipettes. Samples were centrifuged at 2000g for 10 minutes. Subsequently, plasma was collected from the upper layer and frozen at -80°C for later analysis.

Liquid Chromatography

Sample Preparation

To precipitate plasma proteins, 150 µL of acetonitrile containing internal standard and 30 µL of ice-cold acetonitrile were added to 30 µL of plasma. The mixture was vortexed for 10 minutes and centrifuged at 15,000 x g for 10 minutes. The supernatant was transferred to a 96-well plate (Fisher Scientific) for liquid chromatograph-tandem mass spectrometry (LC-MS/MS).

Sample Specificity

The chromatograms of blank plasma versus blank plasma spiked with internal standard (CE302) showed that the blank plasma did not interfere with tofacitinib and internal standard determination.

Calibration Curve

Analytical curves were constructed with 12 nonzero standards by plotting the tofacitinib peak area ratio to the internal standard versus the concentration in plasma. The concentration range was evaluated from 1 to 10000 ng/mL for drug level quantification in plasma. A blank sample (matrix sample processed without internal standard) was used to exclude contamination or interference. The curve was built with linear regression with weighing ($1/X^2$). The linearity of the relationship between peak area ratio and concentration was demonstrated by the correlation coefficients ($r = 0.9990$).

Quality Control (QC) Samples

The accuracy and precision were evaluated at four concentration levels (2 ng/mL, 400 ng/mL, 4500 ng/mL, and 9000 ng/mL) with three individual replicates at each concentration. The QC stock solution was prepared from separate weighing. QC samples were prepared at four levels (2 ng/mL, 400 ng/mL, 4500 ng/mL, and 9000 ng/mL). QC samples were run before, in the middle, and after running the samples. At least 50% of QCs at each level were within 15% of their nominal concentration. The intra-batch precision was calculated and expressed as relative standard deviation. Data indicate that the assay method was reliable and reproducible.

Analysis

Tofacitinib concentrations in mouse plasma were determined by a liquid chromatography tandem mass spectrometry (LC-MS/MS) method developed and validated for this study. The LC-MS/MS method was performed using an AB-4500 Qtrap (Sciex, Concord, ON, Canada) mass spectrometer with electrospray ionization source interfaced with a Shimadzu high-performance LC system. Separation was performed on an XBridge C18 column (50 × 2.1 mm ID, 3.5 µm; Waters, Milford, MA, USA) at a flow rate of 0.4 mL/minute. The mobile phase consisted of A (water with 0.1% formic acid) and B (acetonitrile with 0.1% formic acid). The gradient was 0.0-0.5 minutes, 2% B;

0.5-2.0 minutes, 2-95% B; 2.0-3.6 minutes, 95% B; and 3.6-4.1 minutes, 95-2% B. The mass spectrometer was operated in positive mode with multiple reaction monitoring for analysis. The multiple reaction monitoring transitions were m/z 313.1 > 173.1 for tofacitinib and 455.2 > 425.2 for the internal standard. The gas temperature was 500°C with an ionspray voltage of 5500 V, gas 1 and gas 2 of 30 psi, and curtain gas of 30 psi. Analyst Software (version 1.6) from Applied Biosystems (MDS SCIEX; Carlsbad, CA, USA) was used to control the LC-MS/MS system, as well as for data acquisition and processing. All pharmacokinetic parameters were estimated using non-compartmental analyses with Phoenix WinNonlin software (Certara, Princeton, NJ).

Tofacitinib Mouse Chow

Low-dose (5 mg/kg) and high-dose (30 mg/kg) chow was manufactured by Research Diets (New Brunswick, NJ). To determine the initial tofacitinib content in the chow, chow from two cages of mice was weighed daily for a week to determine the daily chow consumption per cage. The average chow consumption for each mouse was then calculated, and low- and high-dose chow was formulated based on average consumption. For the peripheral immune analysis, male and female mice were placed on low-dose, high-dose, or normal chow (control animals) for two weeks prior to harvest.

Blood Leukocyte Collection

Peripheral immune cells were harvested as previously described (9). At the time of harvest, mice were euthanized with sodium pentobarbital, whole blood was collected from the vena cava and measured using a 1 mL syringe (BD Biosciences, Franklin Lakes, NJ), and transferred to a BD Vacutainer® blood collection tube (BD Biosciences) coated with 3.6 mg of EDTA. Red blood cells were lysed with 9.5 mL red blood cell lysis buffer [150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA (Thermo Fisher Scientific) with 13.8 mM HEPES, pH 7.2-7.5 (Thermo Fisher Scientific)] for 20 minutes on a rocker at room temperature. Leukocytes were pelleted (1000 rpm, 10 minutes, 4°C, with brake), supernatant siphoned off, washed twice with flow cytometry buffer [1X PBS, 2% FBS (Thermo Fisher Scientific), 0.1% NaN₃] and resuspended in 1 mL flow cytometry buffer. Cells were counted by hemocytometer (Hausser Scientific, Horsham, PA), and kept on ice until staining for flow cytometry.

Flow Cytometry

Intracellular Perforin and Granzyme B Staining of NK-92 Cells

All samples were washed and resuspended at a density of $\leq 10^6$ cells/25 μ L, plated in U-bottom 96-well plates (Fischer cat #07-200-760), and spun down at 1200 rpm for 10 minutes. Samples were incubated with 10 μ g/mL human TruStain FcX™ blocking solution (Biolegend cat #422302; RRID : AB_2818986) at 4°C for 30 minutes prior to immune staining. Following blocking stage, NK-92 cells were stained with CD56 and HLA and washed with flow buffer (PBS + 2% FBS). Cells were then permeabilized using Cytofix/cytoperm (BD cat #554714; RRID : AB_2869008) and stained with antibody

for perforin (Biolegend cat #353303; RRID : AB_10915476) and granzyme B (Biolegend cat #515403; RRID : AB_2114575). Control stains were performed with non-specific IgG antibody (Biolegend cat #400111; RRID : AB_2847829 and #400137). Cells were then transferred to polystyrene tubes (12x75 mm) (BD Biosciences) and analyzed on a BD LSRFortessa™ flow cytometer with FACSDiva™ software (BD Biosciences) and FlowJo (FlowJo, Ashland, OR).

NK-92 and Primary NK Cytotoxicity Assays

Following collection and wash, co-cultures of NK and K-562 cells were incubated with Fixable Viability Dye eFluor™ 506 (1:500) (eBioscience cat #65-0866-14) during the blocking stage. Samples were then incubated with surface stains CD56 (Biolegend cat #318318; RRID : AB_604107), CD11a (Biolegend cat#301207; RRID : AB_10660819), and CD71 (Biolegend cat #334110; RRID : AB_2563117) at 4°C for 30 minutes. K-562 cells were identified as CD56-, CD11a-, CD71+. Samples were fixed using Stabilizing Fixative (BD cat #338036; 1:3 dilution).

iNeurons

All samples were washed, resuspended at a density of $\leq 10^6$ cells/25 μ L, plated in U-bottom 96-well plates, and blocked at 4°C for 30 minutes prior to staining. Cells were then stained for annexin V (Invitrogen cat #12-8102-69) and with the viability dye 7-amino-actinomycin D (7AAD; Invitrogen cat #00-6993-50), according to the manufacturer's instructions, and fixed for analysis, as above, consistent with previously reported protocols in neurons (43, 44).

Mouse Peripheral Immune Cells

All samples were washed and resuspended at a density of $\leq 10^6$ cells/25 μ L, plated in U-bottom 96-well plates (Fischer), and spun down at 1200 rpm for 10 minutes. Samples were incubated with 10 μ g/mL mouse TruStain FcX™ blocking solution (Biolegend cat #101320; RRID : AB_1574975) at 4°C for 30 minutes prior to staining. Samples were incubated with antibodies against myeloid and lymphoid surface markers as previously described (9). In brief, cells were stained with antibodies against CD45, CD11b, Ly6C, and Ly6G to analyze myeloid populations and CD45, CD3, CD4, CD8, NK1.1, and CD49b to analyze lymphocyte and NK cell populations.

Statistics

All statistics were performed using GraphPad Prism version 8.0.0 (San Diego, CA). All datasets were assessed for normality using normality using Shapiro-Wilk (45). For comparing between two groups, either a two-tailed Student's t-test (normally distributed data) or Mann-Whitney (non-normally distributed data) were used. For cytokine expression by NK-92 cells a paired t-test or a Wilcoxon test (paired data with non-normal distribution) was used when data was not normally distributed. A Wilcoxon test was used for comparing NK-92 cytotoxicity to iNeurons and comparing primary NK cell cytotoxicity to K-562 cancer cells. For comparing peripheral immune cell levels, two-way ANOVA with multiple comparisons was used. *P*-values < 0.05 were considered statistically significant.

RESULTS

Tofacitinib Inhibits NK-92 Cells Function *In Vitro*

Previous studies demonstrate that tofacitinib lowers NK cell levels *in vivo* (34–36, 46); however, little is known about the effect of tofacitinib on NK cell activation. Blocking NK cell activation in addition to lowering levels could potentially increase tofacitinib efficacy for treating NK cell-mediated diseases, such as ALS. Thus, we explored whether tofacitinib reduces NK cell cytotoxicity, cytokine production, and trafficking *in vitro*. We initially employed a commercially available NK cell line, NK-92 cells, and two treatment paradigms to explore the impact of tofacitinib on NK cell function (**Figure 1A**). In the first treatment paradigm (P1, intervention treatment) NK-92 cells were activated with IL-15 for two hours (30–32) and cultured overnight in the presence of tofacitinib. In the second paradigm (P2, prevention treatment), NK-92 cells were first pre-treated with tofacitinib overnight and then activated for two hours with IL-15. In parallel, Unstimulated cells (which received no IL-15 stimulation, serum stimulation, or tofacitinib treatment) were also cultured overnight and analyzed simultaneously with P1 or P2 NK-92 cells. For both paradigms, NK-92 cells were further divided into two groups: NK-92 cells cultured with IL-15 without tofacitinib (Stimulated) and NK-92 cells cultured with both IL-15 and tofacitinib (Treated). This resulted in a total of five NK-92 groups (Unstimulated, P1 Stimulated, P1 Treated, P2 Stimulated, and P2 treated) that were analyzed in parallel.

First, we confirmed that tofacitinib treatment blocks IL-15 signaling in NK-92 cells in both intervention and prevention paradigms. Tofacitinib disrupts JAK/STAT signaling by blocking STAT protein phosphorylation (47). Therefore, we measured phosphorylated STAT1 (P-STAT1) levels in Unstimulated, Stimulated, and Treated NK cells and normalized values levels in Untreated NK-92 cells to account for run-to-run variation. Immunoblot analysis indicated that tofacitinib treatment significantly reduced P-STAT1 in both culture paradigms (10-fold in P1 and 13 fold in P2, **Figure 1B**) demonstrating that tofacitinib blocks IL-15 signaling in NK-92 cells.


We next tested whether tofacitinib treatment suppresses NK cell function by assessing cytotoxicity, the intrinsic ability of NK-92 cells to eliminate other cells. NK-92 cells in both intervention and prevention treatment paradigms (Unstimulated, Stimulated, or Treated) were co-cultured with K-562 leukemia cells. K652 cell death, as measured by cellular viability dye *via* flow cytometry, was used to quantify NK-92-killing activity (48) (**Figure 1C**); cytotoxicity of Stimulated and Treated NK-92 cells was normalized to Unstimulated NK-92 cells. We found that IL-15-treated NK-92 cells doubled the rate of K-562 cancer cells killing under both paradigms. However, under both intervention and prevention treatment paradigms, blocking IL-15 with tofacitinib significantly reduced the ability of NK-92 cells to induce K-562 cell death, showing that tofacitinib reduces the ability of NK cells to eliminate target cells. To ensure that tofacitinib is suppressing NK-92 cytotoxicity rather than reducing cellular viability, we also examined NK-92 survival

using viability dye. We found no significant differences in NK-92 viability following tofacitinib treatment (data not shown).

To support these findings, we next examined the impact of tofacitinib on NK-92 expression of intracellular granzyme B and perforin, both of which play key roles in NK cell-mediated cytotoxicity (49). Intracellular granzyme B and perforin levels from Unstimulated, Stimulated, or Treated NK-92 cells (**Figure 1D**) were quantified by the median fluorescent intensity (MFI) from intracellular flow cytometry; values from Stimulated and Treated NK-92 cells were then normalized to the MFI from Unstimulated NK-92 cells. We found that tofacitinib significantly lowered intracellular perforin levels in the prevention paradigm (P2), with a trending reduction in the intervention paradigm (P1). Tofacitinib also induced a trending reduction towards reduced granzyme B levels. These data suggest tofacitinib may reduce NK cell cytotoxicity, partly by suppressing the expression of proteins that induce target cell death.

In addition to direct cytotoxicity, we examined the ability of tofacitinib to suppress NK cell cytokine production, which enhances neuroinflammation in ALS (7). NK-92 cells were cultured under both paradigms, and cytokine IL-10, TNF- α , and IFN- γ mRNA expression levels were measured by qRT-PCR and normalized to Unstimulated cells. Overall, TNF- α , IL-10, and IFN- γ gene expression increased in both paradigms following IL-15 stimulation, but this increase was reversed by tofacitinib treatment (**Figure 1E**). To confirm these findings, we next examined the secretion of pro-inflammatory and pro-apoptotic factors using a bead-based multiplex analysis paired with flow cytometry. Conditioned media from Stimulated and Treated culture conditions was analyzed for levels of IL-10, TNF- α , IFN- γ , granzyme B, and perforin. Similar patterns of NK cell suppression were seen following both tofacitinib treatment paradigms. As observed with qRT-PCR, both IL-10 and IFN- γ levels were suppressed during the P1 and P2 treatment paradigms (**Figure 1F**). Similarly, granzyme B and perforin expression were suppressed following the P2 treatment paradigm, demonstrating that tofacitinib suppresses the release of pro-inflammatory and pro-apoptotic factors by NK-92 cells. Together, these data demonstrate that tofacitinib suppresses the ability of NK cells to generate cytokines in addition to blocking their cytotoxicity in response to pro-inflammatory stimulation.

Next, we explored whether tofacitinib protects neurons from NK cell-mediated cytotoxicity in an *in vitro* ALS model. To do so, we co-cultured NK-92 cells with iPSC-derived iNeurons. Two iNeuron cell lines were used: one derived from a control participant and one derived from an ALS participant (50). Following differentiation and ten days of growth, iNeurons were co-cultured for four hours with IL-15-stimulated NK-92 cells with and without tofacitinib. Annexin V and 7AAD were used as markers to quantitate iNeuron cell death by flow cytometry (43, 44), and mCherry was used to identify iNeurons within the co-culture (**Figure 2A**). However, dead NK-92 cells autofluoresce and appear positive for mCherry, and NK-92 cells cultured in iNeuron media #3 display increased NK cell death. Thus, dead NK-92 cells also appeared



within the Annexin V+ and 7AAD+ gates for iNeurons, potentially skewing the data. To account for this this, we compared Annexin V and 7AAD flow plots for mCherry+ iNeurons versus mCherry+ NK-92 cells cultured alone in iNeuron media and found that NK 7AAD fluorescence levels for NK cells were higher than that of iNeurons. Thus, dead iNeurons were identified based on moderate 7AAD staining; cell

death rates for iNeurons co-cultured with Stimulated and Treated NK-92 cells were then examined. We found that control-derived iNeurons showed similar rates of cell death whether cultured with or without tofacitinib treatment (**Figure 2B**). In contrast, there was a significant reduction in the rate of cell death for ALS-derived iNeurons that were cultured with Treated NK cells versus Stimulated NK cells. Together these results demonstrate that tofacitinib can protect ALS neurons from NK cell-mediated cytotoxicity.

Tofacitinib Inhibits Primary NK Cells Function *Ex Vivo*

We next extended these findings to determine whether tofacitinib suppresses cytotoxicity in primary NK cells from control and ALS participants (see **Table 1** for demographics). Primary NK cells were isolated from the peripheral blood of control and ALS participants. We first confirmed that tofacitinib suppresses JAK/STAT signaling in primary NK cells from control and ALS participants, similar to NK-92 cells. As measured by STAT1 phosphorylation *via* immunoblotting, tofacitinib significantly reduced P-STAT1 levels in primary ALS and control NK cells versus those stimulated with IL-2 and IL-15 (**Figure 3A**). Next, cytokine gene expression was examined in control and ALS primary NK cells following cytokine stimulation and treatment (**Figure 3B**). In ALS NK cells, tofacitinib treatment significantly decreased *TNF-α* and *IFN-γ* expression from primary ALS NK cells. A similar trend was observed in the cytokine gene expression of control primary NK cells. As with the NK-92 cell line, we also examined whether tofacitinib inhibits the release of pro-inflammatory and pro-apoptotic factors using a multiplex analysis. Conditioned media from primary NK cells cultured with IL-15 with and without tofacitinib was analyzed for the secretion of *TNF-α* and *IFN-γ* (**Figure 3C**). There was a trend towards reduced *TNF-α* secretion from primary NK cells isolated from control participants and reduced *TNF-α* and *IFN-γ* secreted from primary NK cells isolated from ALS participants.

Finally, we examined whether tofacitinib suppresses the cytotoxicity of primary NK cells isolated from control and ALS participants. After isolation, primary NK cells were co-cultured with K-562 target cancer cells, and the rate of K-562 cell death was used to quantitate primary NK cell cytotoxicity. Since K-562 viability can fluctuate, the rate of K-562 cell death in co-culture was normalized to the rate of K-562 cells cultured alone (**Figure 3D**). The cytotoxicity of both control and ALS primary Stimulated NK cells (IL-2 + IL-15) did not significantly differ from NK cells stimulated with IL-2 alone (data not shown). In contrast, primary NK cells treated with tofacitinib displayed significantly lower cytotoxicity to K-562 cells than Stimulated NK cells (**Figure 3E**). As with NK-92 cells, exposure to tofacitinib did not alter the viability of primary NK cells (data not shown). Together, these results demonstrate that primary NK cells are already stimulated in the peripheral blood of control and ALS participants, but tofacitinib can nevertheless suppress primary NK cell cytotoxicity by inhibiting JAK/STAT signaling.

TABLE 1 | Subject demographics for primary NK cell analyses.

	Western Blot		Cytokine Gene Expression		Cytokine Protein Secretion		Cytotoxicity	
	Control (n = 3)	ALS (n = 4)	Control (n = 3)	ALS (n = 8)	Control (n = 5)	ALS (n = 4)	Control (n = 12)	ALS (n = 32)
Age (Mean ± SD) years	70.5 ± 5.3	60.7 ± 13.4	66.2 ± 10.9	65.0 ± 8.2	69.32 ± 3.9	65.61 ± 6.7	61.7 ± 13.3	64.2 ± 9.0
Sex (%) male	66.6	25.0	33.3	37.5	60.0	50.0	50.0	56.3
ALSFRS-R at Blood Draw	N/A	23.0 ± 7.7	N/A	28.4 ± 10.3	N/A	35.8 ± 6.1	N/A	26.1 ± 8.3
Site of Onset	N/A	Bulbar (50.0%) Cervical (25.0%) Lumbar (25.0%)	N/A	Bulbar (25.0%) Cervical (25.0%) Lumbar (50.0%)	N/A	Bulbar (50.0%) Cervical (25.0%) Lumbar (25.0%)	N/A	Bulbar (18.8%) Cervical (34.4%) Lumbar (46.8%)
Race	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (75.0%) Black (25.0%) Asian (0%)Not reported (0%)	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (100%) Black (0%)Asian (0%)Not reported (0%)	White (90.6%) Black (9.4%) Asian (0%)Not reported (0%)
Ethnicity	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)	Not Hispanic (100%)Hispanic (0%)Not reported (0%)
Time from Onset to Collection (Mean ± SD) years	N/A	5.0 ± 4.2	N/A	7.7 ± 6.8	N/A	2.7 ± 1.6	N/A	4.1 ± 3.9
Time from Diagnosis to Collection (Mean ± SD) years	N/A	3.6 ± 3.4	N/A	5.2 ± 6.7	N/A	1.6 ± 1.5	N/A	2.7 ± 3.6

N/A, not applicable.

Tofacitinib Pharmacokinetics in Mice

Next, we wanted to optimize tofacitinib pharmacokinetics to administer to ALS mice in future studies, since NK cells are implicated in ALS pathogenesis (7, 13). However, symptoms in ALS mice do not emerge until after 90 days of age, and their lifespan is about 160 days of age in low-copy mouse strains (9). Therefore, preclinical studies of tofacitinib in SOD1^{G93A} mice will require long-term treatment. Unfortunately, previous studies testing tofacitinib in mice were either short-term studies with daily gavage (35) or longer-term studies using osmotic minipumps (51). For long-term diseases, administering tofacitinib daily by gavage is not logistically feasible and can induce significant animal losses (52). Conversely, minipumps cannot administer high treatment doses and require repeated surgeries. Thus, we wished to evaluate the efficacy of tofacitinib formulated into chow as a method of long-term administration for future preclinical studies.

Although tofacitinib pharmacokinetics had been performed in rats and human participants, little data are available in mice. Therefore, our first step was to assess tofacitinib pharmacokinetics after a single orally (PO, *per os*, gavage) or intravenously (IV) administered tofacitinib dose to male and female C57BL/6 mice. Blood was collected at multiple time points (5, 10, 15, 30, 60, 120, 240, 420, 960, 1440 minutes) post IV and PO administration and the kinetics of blood tofacitinib assessed. Tofacitinib bioavailability was roughly 37% in both male and female mice, *i.e.*, roughly 37% of the initial dose administered orally reaches the peripheral blood (Table 2). Interestingly, we observed that other pharmacokinetic parameters differed between male and female mice. For

instance, the maximal plasma level was higher in female versus male mice after both IV and PO dosing, while drug clearance was higher in male mice. These data indicate that tofacitinib can be administered orally by chow with similar drug uptake in males and females, though there may be sex-specific differences in drug metabolism resulting in altered plasma levels.

Efficacy of Low- and High-Dose Tofacitinib in Mouse Chow

Finally, we tested tofacitinib efficacy formulated in chow on NK cell levels in mice. Based on the pharmacokinetic data, chow was formulated to deliver a daily dose of 5 mg/kg (low-dose) or 30 mg/kg (high-dose) to male and female WT control mice (*i.e.*, WT littermates on an SOD1^{G93A} background) for two weeks. At the end of the treatment period peripheral immune cell levels were assessed by flow cytometry for the percentage and total number of NK cells, neutrophils, Ly6C- monocytes, Ly6c+ monocytes, CD4 T cells, and CD8 T cells. Both low- or high-dose tofacitinib treatment significantly lowered NK cell percentage in a dose-dependent manner (Figure 4A). Moreover, both doses significantly reduced total NK cell counts in peripheral blood versus normal chow, and there was a trend towards fewer circulating NK cells in of high- versus low-dose mice (Figure 4B). In contrast, tofacitinib treatment did not significantly reduce the percentage or total number of neutrophils, Ly6C+ monocytes, CD4 T cells, or CD8 T cells. Interestingly, high-dose mice had significantly lower percentage and total number of circulating Ly6C- monocytes, which is consistent with our previous study utilizing NK cell depletion (13). Together, these results demonstrate that tofacitinib can be




FIGURE 3 | Tofacitinib inhibits primary NK cells *in vitro*. Primary NK cells were enriched from the whole blood of control and ALS participants. **(A)** P-STAT1 was assessed using Western blot. Primary NK cells were incubated with IL-2 alone, IL-2 + IL-15, or IL-2 + IL-15 + tofacitinib for 2 hours. Protein extracts were resolved by SDS-PAGE and immunoblotted for total STAT1, phosphorylated STAT1 (P-STAT1), and α -tubulin (internal reference). Graph represents densitometric analysis where total STAT1 and P-STAT1 signals were normalized to α -tubulin then normalized to NK cells receiving IL-2 alone; n = 2-4 participants. **(B)** Cytokine gene expression was assessed using qRT-PCR for *TNF- α* and *IFN- γ* . Data were normalized to γ H2AX expression and normalized to the IL-2 NK cells; n = 3-8 participants. **(C)** Extracellular expression of *TNF- α* and *IFN- γ* was assessed for primary NK cells cultured with IL-15 \pm tofacitinib (n = 5 control and n = 4 ALS). **(D)** Primary NK cells were assessed for cytotoxicity. Primary NK cells were cultured for two hours with K-562 cancer cells (1:1 ratio) + IL-15 \pm tofacitinib; K-562 cell death was assessed using flow cytometry to quantitate e506 viability dye fluorescence. **(E)** Data were quantitated by normalizing to K-562 cells cultured without NK cells; n = 12 control and n = 32 ALS. For **(A, B)**, data are presented as mean \pm SEM with dashed line showing cells cultures with IL-2 alone; comparisons were made by Student's t-test. For **(C)**, comparisons were made using a paired t-test. For **(E)**, comparisons were made by Wilcoxon test to assessed paired, non-normally distributed data. **P* < 0.05, ****P* < 0.001, *****P* < 0.0001.

TABLE 2 | Tofacitinib pharmacokinetic parameters in plasma following IV and PO administration.

Route Unit	Sex	Dose mg/kg	C0/Cmax ng/mL	Tmax h	AUC ₍₀₋₂₄₎ h*ng/mL	AUC _(0-inf) h*ng/mL	t½ h	CL/CL_F mL/h/kg	Vss/Vz_F mL/kg	%F %
IV	M	10	3554.4	N/A	676.76	678.09	1.85	14747.23	39278.78	N/A
PO	M	20	960	0.25	505.74	508.48	0.91	39332.99	51817.31	37.4
IV	F	10	6516.9	N/A	980.54	982.90	0.72	10173.94	10549.83	NA
PO	F	20	1114.3	0.167	713.26	719.57	0.90	27794.47	36093.12	36.4

IV, intravenous, PO, per os; C0, concentration at time 0; Cmax, maximum observed concentration; Tmax, time to reach Cmax; AUC₍₀₋₂₄₎, area under the concentration-time curve from time zero to 24 hours; AUC_(0-inf), area under the concentration-time curve from time zero to infinite; CL, systemic clearance; CL_F, apparent clearance; Vss, volume of distribution at steady state; Vz_F, volume of distribution associated with the terminal elimination phase; terminal elimination half-life (t½) was calculated based on data points (≥3) in the terminal phase with correlation of coefficient >0.90; %F, bioavailability; N/A, not applicable.

administered in chow mouse models and suppresses NK cell levels in a dose-dependent manner.

DISCUSSION

Previous studies have shown that tofacitinib treatment suppresses NK cell levels (34–36, 46), but there is limited information on the impact of tofacitinib on NK cell function (41). Similarly, preclinical mouse disease studies of tofacitinib have been short-term or used administration routes unsuitable to long-term studies. Addressing these shortcomings is of utmost importance to test tofacitinib for regulating NK cell function and counts in future preclinical ALS studies, since NK cells are implicated in ALS progression (7, 13). Therefore, in the current study, we evaluated tofacitinib on NK cell function *in vitro* and conducted a pharmacokinetic study *in vivo*. We used the pharmacokinetic data to formulate tofacitinib in chow, a suitable format for long-term oral administration. We evaluated

the impact of a 2-week tofacitinib chow regimen on circulating NK cell levels in WT mice. We found tofacitinib suppressed IL-15-mediated JAK/STAT pathway stimulation, cytotoxicity to cancer cells and iNeurons, granzyme B and perforin expression, and cytokine expression in the NK-92 cell line. Importantly, in the context of ALS, tofacitinib also significantly lowered cytotoxicity of IL-2/IL-15-stimulated primary NK cells isolated from ALS participants and healthy controls, as well as cytokine levels. Finally, tofacitinib bioavailability was similar in male and female mice, although there were sex differences in some parameters; formulation in chow at both low- (5 mg/kg) and high-dose (30 mg/kg) tofacitinib after 2 weeks lowered peripheral NK cell levels in WT control mice.

These findings suggest that tofacitinib may be a viable therapeutic strategy to regulate the NK cell population in ALS. NK cells accumulate in the spinal cord of ALS mice (8, 13, 19, 53). In individuals with ALS, NK cells are increased in the peripheral blood (10, 11) and co-localize with motor neurons




FIGURE 4 | Impact of orally administered tofacitinib on peripheral immune populations in mice. WT control mice (half male and half female) were treated for two weeks with low- (5 mg/kg) and high- (30 mg/kg) dose tofacitinib administered in standard chow. Immune cells were then analyzed in peripheral blood using flow cytometry; (A) percentage of all CD45+ immune cells as well as (B) total numbers of cells was examined for six immune populations. Data show mean ± SEM. Comparisons by ANOVA; n = 4 mice per group. *P<0.05, **P<0.01, ***P<0.001; monos, monocytes.

in *postmortem* spinal cord tissue, driving microglial activation *via* IFN- γ expression (7). Indeed, as ALS progresses, motor neurons lose surface markers, which protect against NK cell-mediated cytotoxicity (20), rendering them more susceptible to attack. In addition to increased NK cell levels, they are also more highly activated in individuals with ALS, correlating with disease progression (13). Depleting NK cells from SOD1^{G93A} ALS mice extends survival (7, 13). Thus, reducing NK cell levels, blocking NK cell cytotoxicity, and suppressing IFN- γ release from NK cells may slow motor neuron loss and suppress central nervous system inflammation, increasing survival in ALS.

Previous studies have established that tofacitinib blocks immune cell activation and activity by interfering with the JAK/STAT pathway (25), promoting pro-inflammatory cytokine signaling between cells (27, 54, 55). Blocking cytokines, such as IFN- γ , with tofacitinib prevents inflammatory T cell activation, which effectively treats autoimmune disorders, such as rheumatoid arthritis, ulcerative colitis, and psoriasis (22–24). In the case of NK cells, blocking JAK/STAT signaling suppresses the IL-15 pathway (33), which is a crucial mediator of both NK cell survival and activation (29, 56, 57). This likely explains the reduced peripheral NK cell levels observed after tofacitinib treatment in both mouse and humans (34–36, 46). However, in addition to maintaining NK cell homeostasis, IL-15 is also a potent stimulator of NK cell function (30–32). Thus, tofacitinib should also block IL-15-mediated NK cell activation. Our current study definitively shows this: tofacitinib treatment suppresses pro-inflammatory cytokine production and cytotoxicity in both NK-92 cells and primary NK cells. This is particularly salient to ALS, since direct NK cell cytotoxicity as well as IFN- γ production likely contribute to disease progression (7). The importance of these findings is further corroborated by our results showing that tofacitinib significantly reduces NK cell cytotoxicity towards iNeurons generated from ALS patient-derived iPSCs.

The current study also suggests that tofacitinib suppresses NK cell levels in an ALS mouse model. However, although preclinical mouse models are crucial for evaluating drug efficacy *in vivo*, no comprehensive studies have examined tofacitinib pharmacokinetics nor the long-term impact of the drug on peripheral immunity in mice. There are challenges associated with long-term drug administration. One possible solution is the use of osmotic minipumps as it has been previously shown (51). However, minipumps typically administer either a low drug dose over a long period of time or a high dose over a short period of time. A higher dose of tofacitinib, such as 30 mg/kg, would require frequent pump replacement and multiple surgeries. Not only is this logistically difficult, but frequent surgeries would be potentially life-threatening for mice in advanced stages of disease. In contrast, daily oral tofacitinib administration to mice *via* gavage is not logistically feasible over long time periods either as the rate of death associated with technique is 15% over a six week period (35, 52). Moreover, these previous studies did not examine tofacitinib pharmacokinetics – particularly bioavailability – meaning the final concentration in the peripheral blood following oral administration was not known. In the present study we found that tofacitinib bioavailability in mice (around 37%) differed from

humans, where bioavailability is 74% (58). Perhaps unsurprisingly, bioavailability in mice is closer to that in rats (29%) (59). Interestingly, we found that plasma tofacitinib levels differed between male and female mice, even after IV administration, suggesting the sexes may clear the drug at different rates. These sex-specific tofacitinib pharmacokinetics differences are potentially important for future ALS treatment, since we have previously described sex-based immune differences in ALS (12, 13).

Consistent with other methods of tofacitinib administration, treating mice orally with tofacitinib in chow successfully suppressed circulating NK cell levels in a dose-dependent manner in WT mice on a SOD1^{G93A} genetic background. Together with our *in vitro* findings, these results suggest that tofacitinib modulates NK cell levels and activity and should be tested in preclinical mouse models of ALS. However, an in-depth series of studies will be required, as the mechanisms of NK cell involvement in ALS is incompletely understood. One mechanism by which NK cells contribute to ALS is the destruction of damaged motor neurons within the CNS, as motor neurons are uniquely vulnerable to NK cells during disease progression (20). Alternatively, NK cells may be involved in other disease mechanisms. NK cells may play an important role in driving early microglial activation (7) which has been implicated in ALS pathology (60–62), and they may also contribute to peripheral nerve damage in ALS, as increased expression of major histocompatibility complex I was associated with slower disease progression in mouse models of ALS (63). The role of NK cells in the loss of neuromuscular junction (NMJ) integrity during ALS has also not been examined.

Preclinical studies must also account for the impact of tofacitinib on other immune cell populations that modulate ALS progression, both in the periphery and the CNS. Immune cells are both protective and destructive in ALS (2, 10), so preserving protective immune function is of the utmost importance when designing and utilizing immune-based therapies. While the current study demonstrated that tofacitinib suppresses NK cell numbers in the peripheral blood, changes were also observed in other cell populations. Ly6C-monocytes, which patrol the body and are involved in fibrosis and wound repair (64), were significantly reduced in mice treated with the higher tofacitinib dose; analogous monocytes in human patients may have a protective effect (65). Similarly, there was a trend towards reduced CD4 and CD8 T cell levels following tofacitinib treatment, particularly in mice treated with the high dose. While these observations did not reach statistical significance, it is important to account for these changes, as these immune cell types play a central role in ALS, in particularly CD4 T cells (4, 10). Since the cellular lifespan of NK cells (66–68) is much shorter than that of T cells (69) it may be possible to preserve T cell levels by utilizing on/off drug treatment cycles. This possibility should also be explored in future clinical trials.

In addition, preclinical tofacitinib studies should account for the impact of sex in ALS mouse models. Though the impact of sex on tofacitinib-NK cell interaction was not explored in the current study, we have previously demonstrated that sex alters the impact of several immune cell populations in ALS, including

NK cells (12, 13). Moreover, depletion of NK cells also impacts male and female mice differently, both in terms of survival and neuroinflammation (13); therefore, tofacitinib studies should likewise account for sex differences given the reduction in peripheral NK cell levels following tofacitinib treatment. Altogether, *in vivo* tofacitinib studies in ALS mice should examine a myriad of mechanisms and factors including peripheral and CNS immune cell populations, peripheral and CNS gene expression, motor neuron survival, and NMJ integrity. Studies will need to examine drug dosing, drug timing, and will need to account for the impact of sex.

The current study does have several limitations. First, primary NK cells are more difficult to culture than NK-92 cells and were therefore not co-cultured with iNeurons. iNeurons are also not motor neurons, thus, it is unclear to what degree ALS iNeurons recapitulate true motor neurons *in vivo*. Moreover, in mice, we only examined the effect of tofacitinib on NK cell numbers rather than on NK cell function. Many of the *in vitro* assays require large cell numbers, and tofacitinib treatment reduced overall NK cell levels, making these analyses *in vivo* difficult. Finally, while we have previously shown that both age and sex alter the activity of immune cells during ALS, including NK cells (12, 13), the present study did not explore the impact of these factors on tofacitinib suppression of NK cells. Nonetheless, our results conclusively show that tofacitinib suppresses NK cell function *in vitro*, suppresses NK cell levels *in vivo*, and can be administered orally in chow for use in preclinical ALS mouse models. These findings also indicate tofacitinib may be used to treat long-term diseases mediated by NK cell function, such as ALS.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Michigan Medical School Institutional Review Board. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by University of Michigan Institutional Animal Care & Use Committee.

REFERENCES

- Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. *Continuum (Minneapolis)* (2017) 23(5, Peripheral Nerve and Motor Neuron Disorders):1332–59. doi: 10.1212/CON.0000000000000535
- Murdock BJ, Bender DE, Segal BM, Feldman EL. The Dual Roles of Immunity in ALS: Injury Overrides Protection. *Neurobiol Dis* (2015) 77:1–12. doi: 10.1016/j.nbd.2015.02.017
- Zhao W, Beers DR, Appel SH. Immune-Mediated Mechanisms in the Pathoprotection of Amyotrophic Lateral Sclerosis. *J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol* (2013) 8(4):888–99. doi: 10.1007/s11481-013-9489-x

AUTHOR CONTRIBUTIONS

CF-R, AM, BM, and EF designed the overall study. CF-R, AM, BM, JF, IW-D, CEP, ST, and CP performed *in vitro* studies using NK-92 cells. CF-R, BM, IW-D, ST, and CP performed iNeuron co-culture assays. CF-R, BM, JF, IW-D, CEP, ST, and CP performed *ex vivo* studies using primary NK cells. BM, SG, and EF wrote the IRB protocol. SG and EF recruited human participants for the study. JF and CEP worked with the pharmacokinetic core for the mouse pharmacokinetic studies. BM, JF, and CEP performed the mouse immune studies. CF-R, AM, and BM analyzed the data. CF-R, AM, BM, JF, IW-D, CEP, ST, CP, SG, and EF wrote the manuscript with substantial input from all authors. All authors contributed to the article and approved the submitted version.

FUNDING

This work was partially supported by the U.S. National Institutes of Health (R21NS102960 and R01ES030049 to EF, K23ES027221 to SG, and T32NS0007222 supported AMM-C), the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry (CDC/ATSDR; R01TS000289 to EF), the ALS Association (20-IIA-431 to BM), and the Department of Defense (W81XWH-21-1-0293 to BM). Support was also provided by the Sinai Medical Foundation Neuroscience Scholar Fund and the NeuroNetwork for Emerging Therapies at the University of Michigan.

ACKNOWLEDGMENTS

The authors are grateful to the ALS and control participants in this study and to the staff of the Pranger ALS Clinic. The authors also acknowledge Mrs. Elizabeth Taylor for administrative support, and Drs. Stacey Sakowski Jacoby and Masha G. Savelieff for expert editorial assistance. The authors acknowledge Sean Linkes of the University of Michigan Flow Cytometry Core for his assistance with the analysis of NK cell conditioned media. The authors also acknowledge Bo Wen, Lu Wang, Miao He, and Aleksas Matvekas of the University of Michigan Pharmacokinetics Core for their pharmacokinetic assessment of tofacitinib in mice.

- Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T Cells Support Glial Neuroprotection, Slow Disease Progression, and Modify Glial Morphology in an Animal Model of Inherited ALS. *Proc Natl Acad Sci USA* (2008) 105(40):15558–63. doi: 10.1073/pnas.0807419105
- Henkel JS, Beers DR, Siklos L, Appel SH. The Chemokine MCP-1 and the Dendritic and Myeloid Cells it Attracts Are Increased in the Msod1 Mouse Model of ALS. *Mol Cell Neurosci* (2006) 31(3):427–37. doi: 10.1016/j.mcn.2005.10.016
- Butovsky O, Siddiqui S, Gabrieli G, Lanser AJ, Dake B, Murugaiyan G, et al. Modulating Inflammatory Monocytes With a Unique microRNA Gene Signature Ameliorates Murine ALS. *J Clin Invest* (2012) 122(9):3063–87. doi: 10.1172/JCI62636

7. Garofalo S, Coccozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, et al. Natural Killer Cells Modulate Motor Neuron-Immune Cell Cross Talk in Models of Amyotrophic Lateral Sclerosis. *Nat Commun* (2020) 11(1):1773. doi: 10.1038/s41467-020-15644-8
8. Finkelstein A, Kunis G, Seksenyan A, Ronen A, Berkutzi T, Azoulay D, et al. Abnormal Changes in NKT Cells, the IGF-1 Axis, and Liver Pathology in an Animal Model of ALS. *PLoS One* (2011) 6(8):e22374. doi: 10.1371/journal.pone.0022374
9. Figueroa-Romero C, Guo K, Murdock BJ, Paez-Colasante X, Bassis CM, Mikhail KA, et al. Temporal Evolution of the Microbiome, Immune System and Epigenome With Disease Progression in ALS Mice. *Dis Models Mech* (2019) 13(2). doi: 10.1242/dmm.041947
10. Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. *JAMA Neurol* (2017) 74(12):1446–54. doi: 10.1001/jamaneurol.2017.2255
11. Gustafson MP, Staff NP, Bornschlegl S, Butler GW, Maas ML, Kazamel M, et al. Comprehensive Immune Profiling Reveals Substantial Immune System Alterations in a Subset of Patients With Amyotrophic Lateral Sclerosis. *PLoS One* (2017) 12(7):e0182002. doi: 10.1371/journal.pone.0182002
12. Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-Specific Manner. *Neurology(R) Neuroimmunol Neuroinflamm* (2021) 8(2). doi: 10.1212/NXI.0000000000000953
13. Murdock BJ, Famie JP, Piecuch CE, Raue KD, Mendelson FE, Pieroni CH, et al. Natural Killer Cells Associate With Amyotrophic Lateral Sclerosis in a Sex- and Age-Dependent Manner. *JCI Insight* (2021) 6(11). doi: 10.1172/jci.insight.147129
14. Penn I. Cancer is a Complication of Severe Immunosuppression. *Surg Gynecol Obstet* (1986) 162(6):603–10.
15. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of Minocycline in Patients With Amyotrophic Lateral Sclerosis: A Phase III Randomised Trial. *Lancet Neurol* (2007) 6(12):1045–53. doi: 10.1016/S1474-4422(07)70270-3
16. Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, et al. Pentoxifylline in ALS: A Double-Blind, Randomized, Multicenter, Placebo-Controlled Trial. *Neurology* (2006) 66(1):88–92. doi: 10.1212/01.wnl.0000191326.40772.62
17. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of Natural Killer Cells. *Nat Immunol* (2008) 9(5):503–10. doi: 10.1038/ni1582
18. Davies AJ, Kim HW, Gonzalez-Cano R, Choi J, Back SK, Roh SE, et al. Natural Killer Cells Degenerate Intact Sensory Afferents Following Nerve Injury. *Cell* (2019) 176(4):716–28.e18. doi: 10.1016/j.cell.2018.12.022
19. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftoglou SA, Vartanian TK, et al. T Lymphocytes Potentiate Endogenous Neuroprotective Inflammation in a Mouse Model of ALS. *Proc Natl Acad Sci USA* (2008) 105(46):17913–8. doi: 10.1073/pnas.0804610105
20. Song S, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L, et al. Major Histocompatibility Complex Class I Molecules Protect Motor Neurons From Astrocyte-Induced Toxicity in Amyotrophic Lateral Sclerosis. *Nat Med* (2016) 22(4):397–403. doi: 10.1038/nm.4052
21. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. Structure and Function of Major Histocompatibility Complex (MHC) Class I Specific Receptors Expressed on Human Natural Killer (NK) Cells. *Mol Immunol* (2002) 38(9):637–60. doi: 10.1016/S0161-5890(01)00107-9
22. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib Versus Methotrexate in Rheumatoid Arthritis. *N Engl J Med* (2014) 370(25):2377–86. doi: 10.1056/NEJMoa1310476
23. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* (2017) 376(18):1723–36. doi: 10.1056/NEJMoa1606910
24. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for Psoriatic Arthritis in Patients With an Inadequate Response to TNF Inhibitors. *N Engl J Med* (2017) 377(16):1525–36. doi: 10.1056/NEJMoa1615977
25. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection. *J Med Chem* (2010) 53(24):8468–84. doi: 10.1021/jm1004286
26. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The Mechanism of Action of Tofacitinib - An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis. *Clin Exp Rheumatol* (2016) 34(2):318–28.
27. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of Tofacitinib on Lymphocytes in Rheumatoid Arthritis: Relation to Efficacy and Infectious Adverse Events. *Rheumatology* (2014) 53(5):914–8. doi: 10.1093/rheumatology/ket466
28. Sewgobind VD, Quaedackers ME, van der Laan LJ, Kraaijeveld R, Korevaar SS, Chan G, et al. The Jak Inhibitor CP-690,550 Preserves the Function of CD4CD25FoxP3 Regulatory T Cells and Inhibits Effector T Cells. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons* (2010) 10(8):1785–95. doi: 10.1111/j.1600-6143.2010.03200.x
29. Strowig T, Chijioko O, Carrega P, Arrey F, Meixlsperger S, Ramer PC, et al. Human NK Cells of Mice With Reconstituted Human Immune System Components Require Preactivation to Acquire Functional Competence. *Blood* (2010) 116(20):4158–67. doi: 10.1182/blood-2010-02-270678
30. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation With IL-18 or IL-15 in Combination With IL-12: Implications for the Innate Immune Response. *J Immunol* (1999) 162(8):4511–20.
31. Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL. Interleukin-15 Enhances Cytotoxicity, Receptor Expression, and Expansion of Neonatal Natural Killer Cells in Long-Term Culture. *Clin Diagn Lab Immunol* (2004) 11(5):879–88. doi: 10.1128/CDLI.11.5.879-888.2004
32. Allavena P, Giardina G, Bianchi G, Mantovani A. IL-15 is Chemotactic for Natural Killer Cells and Stimulates Their Adhesion to Vascular Endothelium. *J Leukocyte Biol* (1997) 61(6):729–35. doi: 10.1002/jlb.61.6.729
33. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, et al. Tyrosine Phosphorylation and Activation of STAT5, STAT3, and Janus Kinases by Interleukins 2 and 15. *Proc Natl Acad Sci USA* (1995) 92(19):8705–9. doi: 10.1073/pnas.92.19.8705
34. Shimaoka H, Takeno S, Maki K, Sasaki T, Hasegawa S, Yamashita Y. A Cytokine Signal Inhibitor for Rheumatoid Arthritis Enhances Cancer Metastasis via Depletion of NK Cells in an Experimental Lung Metastasis Mouse Model of Colon Cancer. *Oncol Lett* (2017) 14(3):3019–27. doi: 10.3892/ol.2017.6473
35. Llop-Guevara A, Porras M, Cendon C, Di Ceglie I, Siracusa F, Madarena F, et al. Simultaneous Inhibition of JAK and SYK Kinases Ameliorates Chronic and Destructive Arthritis in Mice. *Arthritis Res Ther* (2015) 17:356. doi: 10.1186/s13075-015-0866-0
36. van Gorp E, Weimar W, Gaston R, Brennan D, Mendez R, Pirsch J, et al. Phase I Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons* (2008) 8(8):1711–8. doi: 10.1111/j.1600-6143.2008.02307.x
37. Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. *Neurother J Am Soc Exp Neurother* (2015) 12(2):364–75. doi: 10.1007/s13311-014-0329-3
38. Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, Li X, et al. Abnormal RNA Stability in Amyotrophic Lateral Sclerosis. *Nat Commun* (2018) 9(1):2845. doi: 10.1038/s41467-018-05049-z
39. Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, et al. Direct Conversion of Fibroblasts to Neurons by Reprogramming PTB-Regulated microRNA Circuits. *Cell* (2013) 152(1-2):82–96. doi: 10.1016/j.cell.2012.11.045
40. Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, et al. Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis. *J Pharmacol Exp Ther* (2014) 348(1):165–73. doi: 10.1124/jpet.113.209304
41. Nocturne G, Pascaud J, Ly B, Tahmasebi F, Mariette X. JAK Inhibitors Alter NK Cell Functions and May Impair Immunosurveillance Against Lymphomagenesis. *Cell Mol Immunol* (2020) 17(5):552–3. doi: 10.1038/s41423-019-0320-3
42. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy Among Receptors on Resting NK Cells for the Activation of Natural Cytotoxicity and Cytokine Secretion. *Blood* (2006) 107(1):159–66. doi: 10.1182/blood-2005-04-1351

43. Diaz-Hernandez JI, Moncada S, Bolanos JP, Almeida A. Poly(ADP-Ribose) Polymerase-1 Protects Neurons Against Apoptosis Induced by Oxidative Stress. *Cell Death Differ* (2007) 14(6):1211–21. doi: 10.1038/sj.cdd.4402117
44. Vaz AR, Delgado-Esteban M, Brito MA, Bolanos JP, Brites D, Almeida A. Bilirubin Selectively Inhibits Cytochrome C Oxidase Activity and Induces Apoptosis in Immature Cortical Neurons: Assessment of the Protective Effects of Glycoursodeoxycholic Acid. *J Neurochem* (2010) 112(1):56–65. doi: 10.1111/j.1471-4159.2009.06429.x
45. Razali NM, Wah YB. Power Comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling Tests. *J Stat Mod Anal* (2011) 2(1):21–33.
46. van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. *Arthritis Rheumatol* (2019) 71(5):685–95. doi: 10.1002/art.40780
47. Murray PJ. The JAK-STAT Signaling Pathway: Input and Output Integration. *J Immunol* (2007) 178(5):2623–9. doi: 10.4049/jimmunol.178.5.2623
48. Alter G, Malenfant JM, Altfeld M. CD107a as a Functional Marker for the Identification of Natural Killer Cell Activity. *J Immunol Methods* (2004) 294(1–2):15–22. doi: 10.1016/j.jim.2004.08.008
49. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-Mediated Target-Cell Death and Immune Homeostasis. *Nat Rev Immunol* (2006) 6(12):940–52. doi: 10.1038/nri1983
50. Weskamp K, Tank EM, Miguez R, McBride JP, Gomez NB, White M, et al. Shortened TDP43 Isoforms Upregulated by Neuronal Hyperactivity Drive TDP43 Pathology in ALS. *J Clin Invest* (2020) 130(3):1139–55. doi: 10.1101/648477
51. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage Preservation by Inhibition of Janus Kinase 3 in Two Rodent Models of Rheumatoid Arthritis. *Arthritis Res Ther* (2008) 10(1):R14. doi: 10.1186/ar2365
52. Arantes-Rodrigues R, Henriques A, Pinto-Leite R, Faustino-Rocha A, Pinho-Oliveira J, Teixeira-Guedes C, et al. The Effects of Repeated Oral Gavage on the Health of Male CD-1 Mice. *Lab Anim* (2012) 41(5):129–34. doi: 10.1038/aban0512-129
53. Coccozza G, di Castro MA, Carbonari L, Grimaldi A, Antonangeli F, Garofalo S, et al. Ca(2+)-Activated K(+) Channels Modulate Microglia Affecting Motor Neuron Survival in Hsd1(G93A) Mice. *Brain Behavior Immun* (2018) 73:584–95. doi: 10.1016/j.bbi.2018.07.002
54. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT Signalling in Rheumatoid Arthritis. *Ann Rheum Dis* (2015) 74(6):1311–6. doi: 10.1136/annrheumdis-2014-206028
55. Gertel S, Mahagna H, Karmon G, Watad A, Amital H. Tofacitinib Attenuates Arthritis Manifestations and Reduces the Pathogenic CD4 T Cells in Adjuvant Arthritis Rats. *Clin Immunol (Orlando Fla)* (2017) 184:77–81. doi: 10.1016/j.clim.2017.04.015
56. Lebrech H, Horner MJ, Gorski KS, Tsuji W, Xia D, Pan WJ, et al. Homeostasis of Human NK Cells is Not IL-15 Dependent. *J Immunol* (2013) 191(11):5551–8. doi: 10.4049/jimmunol.1301000
57. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting Edge: Murine Dendritic Cells Require IL-15R Alpha to Prime NK Cells. *J Immunol* (2004) 173(6):3594–8. doi: 10.4049/jimmunol.173.6.3594
58. Gupta PS, Stock TC, Wang R, Alvey C, Choo HW, Krishnaswami S. A Phase 1 Study to Estimate the Absolute Oral Bioavailability of Tofacitinib (CP-690,550) in Healthy Subjects (Abstract 1122902). *J Clin Pharmacol* (2011) 51(9):1348.
59. Lee JS, Kim SH. Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism. *Pharmaceutics* (2019) 11(7). doi: 10.3390/pharmaceutics11070318
60. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-Type Microglia Extend Survival in PU.1 Knockout Mice With Familial Amyotrophic Lateral Sclerosis. *Proc Natl Acad Sci USA* (2006) 103(43):16021–6. doi: 10.1073/pnas.0607423103
61. Henkel JS, Engelhardt JJ, Siklos L, Simpson EP, Kim SH, Pan T, et al. Presence of Dendritic Cells, MCP-1, and Activated Microglia/Macrophages in Amyotrophic Lateral Sclerosis Spinal Cord Tissue. *Ann Neurol* (2004) 55(2):221–35. doi: 10.1002/ana.10805
62. Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, et al. Extracellular Mutant SOD1 Induces Microglial-Mediated Motoneuron Injury. *Glia* (2010) 58(2):231–43. doi: 10.1002/glia.20919
63. Nardo G, Trolese MC, Bendotti C. Major Histocompatibility Complex I Expression by Motor Neurons and Its Implication in Amyotrophic Lateral Sclerosis. *Front Neurol* (2016) 7:89. doi: 10.3389/fneur.2016.00089
64. Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and Macrophage Differentiation: Circulation Inflammatory Monocyte as Biomarker for Inflammatory Diseases. *Biomark Res* (2014) 2(1):1. doi: 10.1186/2050-7771-2-1
65. Zondler L, Muller K, Khalaji S, Bliedhauser C, Ruf WP, Grozdanov V, et al. Peripheral Monocytes are Functionally Altered and Invade the CNS in ALS Patients. *Acta Neuropathol* (2016) 132(3):391–411. doi: 10.1007/s00401-016-1548-y
66. Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, et al. *In Vivo* Kinetics of Human Natural Killer Cells: The Effects of Ageing and Acute and Chronic Viral Infection. *Immunology* (2007) 121(2):258–65. doi: 10.1111/j.1365-2567.2007.02573.x
67. Jamieson AM, Isnard P, Dorfman JR, Coles MC, Raulet DH. Turnover and Proliferation of NK Cells in Steady State and Lymphopenic Conditions. *J Immunol* (2004) 172(2):864–70. doi: 10.4049/jimmunol.172.2.864
68. Lutz CT, Karapetyan A, Al-Attar A, Shelton BJ, Holt KJ, Tucker JH, et al. Human NK Cells Proliferate and Die *In Vivo* More Rapidly Than T Cells in Healthy Young and Elderly Adults. *J Immunol* (2011) 186(8):4590–8. doi: 10.4049/jimmunol.1002732
69. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of Human Lymphocyte Subsets Defined by CD45 Isoforms. *Nature* (1992) 360(6401):264–5. doi: 10.1038/360264a0

Conflict of Interest: BM, SG, and EF are listed as inventors on a patent, Issue number US10660895, held by University of Michigan titled “Methods for Treating Amyotrophic Lateral Sclerosis” that targets immune pathways for use in ALS therapeutics.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Figueroa-Romero, Monteagudo, Murdock, Famie, Webber-Davis, Piecuch, Teener, Pacut, Goutman and Feldman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.